466 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)

Objectives: To report the differences in tolerability and response to treatment in a retrospective series of compensated HCV-cirrhotic patients before and after LT.Material and methods: 43 HCV-cirrhotic patients (mean age 55.2±8.9, 65.1% male, 34.9% female, Child-Pugh class A, genotype 1: 58.1%, 2: 30.2%, 3: 4.7%, 4: 7%) and 17 LT-patients with recurrent HCV-related cirrhosis (mean age 57.4±9.1, 88.2% male, 11.8% female, Child-Pugh A, genotype 1: 64.7%, 2: 17.6%, 3: 5.9%, 4: 11.8%) were included in the analysis.All patients received recombinant or pegylated interferon plus ribavirin at standard dose and duration.No stopping rule was adopted for LT-patients.Results: EVR was reported in 30/43 (69.8%) non-LT and in 8/17 (47.1%)LT-HCV-cirrhotics, SVR in 18/43 (41.9%) and 8/17 (41.1%), respectively.No statistical difference between the two groups was observed.Among LT-patients, only one without EVR achieved SVR.6/43 (13.9%)HCV non-LT-cirrhotics discontinued the treatment, 4/43 (9.3%) due to adverse events; 8/17 (47%) LT-cirrhotics withdrew the treatment, 4/17 (23.5%) due to adverse events, the remnants for lack of response.No statistical difference between the two groups was observed.Adverse events are shown in Table 1.